Domainex
Integrated drug discovery CRO running hit identification to lead optimisation for biotech and pharma clients
Highlights
- New on EvolcAdded 2026-10-28
About Domainex
Domainex provides integrated pre-clinical drug discovery research services, covering target expression, protein production, assay development, high-throughput screening, hit identification, medicinal chemistry for hit-to-lead and lead optimisation, structural and computational biology, ADMET and candidate selection.
Its customers are biotechnology and pharmaceutical companies, patient foundations and academic institutes working globally on new medicines. Work is organised as customer projects and partnerships, and the company also supports clients in biologics, agrochemicals and materials science.
Domainex was founded in 2001 and is registered in Pampisford, UK. It also works from sites in Cambridge and Little Chesterford. The website states that the team includes about 100 scientists, over 90% of them PhD or MSc qualified, and reports three first-in-class candidates nominated in the last three years.
Product: Integrated pre-clinical drug discovery research services, from target expression through to development candidate selection.
Jobs at Domainex
Leadership
- Hayley French · CEOSource: company website
- Ray Boffey · CCOSource: company website
- Andrea Fuller · HR DirectorSource: company website
- Tom Amies · Finance DirectorSource: company website
More biotech & pharma companies
Draig Therapeutics
Develops neuropsychiatric drug therapies for patients with depression and other brain disordersNew on EvolcDrugsrus
Pharmaceutical wholesaling, distribution and export for UK healthcare providers and global buyersNew on EvolcDuke Street Bio
Develops cancer therapies targeting DNA damage repair deficiencies for patients with cancerNew on EvolcEarlham Enterprises
Contract research and genomics services for academic, public-sector, nonprofit and private organisationsNew on EvolcEco Animal Health
Veterinary medicines and vaccines for pig, poultry and cattle producers, sold directly and through distributors in over 70 countriesNew on EvolcElasmogen
Biopharma developing ELN28, a dual-acting TNFα and JAK inhibitor conjugate for hidradenitis suppurativa patientsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Drupal
- Google Tag Manager
- Google reCAPTCHA
- React
- jQuery
- nginx